CSL Share Price

Price Chart 
View CSL's share price performance over a 12 month period.

Financial Calendar 2014
12 Feb - Half Year Results
13 Aug - Full Year Results
15 Oct - AGM
Questions about my Shareholding
Please call CSL's share registry ComputerShare on 1800 646 882 for queries regarding address changes, dividend payments, etc.
Investor Contact
Mark Dehring
Mark Dehring
Head of Investor Relations
Phone: +613 9389 2818
Subscribe to News Alert
To receive the latest updates about CSL, sign up for our email News Alert.

About CSL

CSL Limited has over 10,000 staff in more than 20 countries. We produce many life-saving and life-enhancing medicines that enable thousands of people around the world to lead normal healthy lives. Our headquarters is in Australia and we have substantial manufacturing operations in the US, Germany and Switzerland.

CSL is a global specialty biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent a range of human medical conditions. We produce safe and effective therapies for patients who rely on them for their quality of life, and sometimes for life itself.

ASX Releases

Half Year Results announcement for 2013/14
CSL Limited (ASX:CSL) today announced a net profit after tax (NPAT) of US$646 million for the six months ended 31 December 2013, up US$21 million or 3% on a reported basis when compared to the prior comparable period (PCP). The result included a one-off U.S. antitrust class action litigation settlement of US$64 million, or US$39 million after tax. More.

Prior ASX Releases

>> View the ASX Archive

LinkedIn Twitter Facebook Google+